H. Deckx

430 citations

19 papers · 323 indexed · h-index 11

Impact in

Virology top 10%
- HIV Research and Treatment
Emergency Medicine top 5%
- HIV-related health complications and treatments

Papers in ⓘ

Virology 3
- HIV Research and Treatment 3
Rheumatology 8
- Osteoarthritis Treatment and Mechanisms 8
- Rheumatoid Arthritis Research and Therapies 3

Co-authors: Michael Sension (2 shared papers)Simon Vanveggel (3 shared papers)David A. Wohl (2 shared papers)Chloe Orkin (2 shared papers)Marita Stevens (3 shared papers)F. Eckstein (6 shared papers)Ellen van der Aar (5 shared papers)J.E. Dumont (1 shared paper)
Journals: Osteoarthritis and Cartilage (4 papers)Annals of the Rheumatic Diseases (2 papers)Clinical Infectious Diseases (1 paper)Journal of the International AIDS Society (1 paper)Vaccine (1 paper)
Partner nations: Belgium United States France

In The Last Decade

H. Deckx

19 papers receiving 317 citations

Peers

Countries citing papers authored by H. Deckx

Since Specialization

Citations

This map shows the geographic impact of H. Deckx's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Deckx with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Deckx more than expected).

Fields of papers citing papers by H. Deckx

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Deckx. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Deckx. The network helps show where H. Deckx may publish in the future.

Co-authors

The 25 scholars most cited alongside H. Deckx, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. Deckx Line = papers co-authored together H. Deckx links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1–Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials Clinical Infectious Diseases ·Pablo Tebas, Michael Sension, José Ramón Arribas, Dan Duiculescu, Éric Florence, Chien‐Ching Hung, Timothy Wilkin, Simon Vanveggel, Marita Stevens, H. Deckx, (unknown)	2014	49
2	Selenium deficiency mitigates hypothyroxinemia in iodine-deficient subjects American Journal of Clinical Nutrition ·JB Vanderpas, Bernard Contempré, NL Duale, H. Deckx, N Bebe, AO Longombé, CH Thilly, A. T. Diplock, J.E. Dumont	1993	46
3	Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies HIV Clinical Trials ·Mark Nelson, Richard Elion, C Cohen, Anthony Mills, Sally Hodder, Sorana Segal‐Maurer, Mark Bloch, Will Garner, Bill Guyer, Scott Williams, S.K. Chuck, Simon Vanveggel, H. Deckx, Marita Stevens	2013	46
4	Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo) Antiviral Therapy ·David A. Wohl, Chloe Orkin, Manuela Doroana, José Henrique Pilotto, Somnuek Sungkanuparph, Patrick Yéni, Simon Vanveggel, H. Deckx, Katia Boven	2013	36
5	Evaluation of S201086/GLPG1972, an ADAMTS-5 inhibitor, for the treatment of knee osteoarthritis in ROCCELLA: a phase 2 randomized clinical trial Osteoarthritis and Cartilage ·Thomas J. Schnitzer, María Pueyo, H. Deckx, Ellen van der Aar, Katy Bernard, S Hatch, M. van der Stoep, S. Grankov, D. Phung, O. Imbert, Damien Chimits, K. Müller, Marc C. Hochberg, Henning Bliddal, W. Wirth, F. Eckstein, Philip G. Conaghan	2023	26
6	Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study Vaccine ·François Chappuis, T. Farinelli, H. Deckx, Michal Sarnecki, Oscar Go, Yvonne Salzgeber, Coby Stals	2017	18
7	Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS‐5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip Clinical Pharmacology in Drug Development ·Ellen van der Aar, H. Deckx, Sonia Dupont, Ann Fieuw, Stephane Delage, S. Larsson, André Struglics, Stefan Lohmander, Alain Lalande, Emilie Leroux, David Amantini, Paul Passier	2021	17
8	The design of a randomized, placebo-controlled, dose-ranging trial to investigate the efficacy and safety of the ADAMTS-5 inhibitor S201086/GLPG1972 in knee osteoarthritis SHILAP Revista de lepidopterología ·O. Imbert, H. Deckx, Katy Bernard, Ellen van der Aar, María Pueyo, Nadeem Saeed, Thomas Fuerst, W. Wirth, Philip G. Conaghan, F. Eckstein	2021	16
9	Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors. PubMed ·Michael Sension, H. Deckx	2015	15
10	Vitamin D deficiency in HIV: a shadow on long-term management? PubMed ·Chloe Orkin, David A. Wohl, Andrew E. Williams, H. Deckx	2015	14
11	Study design of a phase 2 clinical trial with a disease-modifying Osteoarthritis drug candidate GLPG1972/S201086: The roccella trial Osteoarthritis and Cartilage ·E. vanderAar, H. Deckx, M. van der Stoep, M. Wooning, Katy Bernard, S. Grankov, O. Imbert, María Pueyo, F. Eckstein	2020	10
12	Test-retest reliability and smallest detectable change (SDC) of MRI-based cartilage thickness analysis in a large multicenter randomized controlled clinical trial of knee osteoarthritis Osteoarthritis and Cartilage ·F. Eckstein, Katy Bernard, H. Deckx, O. Imbert, Alain Lalande, A. Wisser, S. Maschek, W. Wirth	2021	6
13	Comparative Efficacy, Safety and Immunogenicity of Hepavax-Gene TF and Engerix-B Recombinant Hepatitis B Vaccines in Neonates in China The Pediatric Infectious Disease Journal ·Fengcai Zhu, H. Deckx, Raphaele Roten, Bart Michiels, Michal Sarnecki	2016	6
14	Neonatal Alloimmune Thrombocytopenic Purpura Induced by Anti-Bak^a: A Case Report and Review of the Literature Acta Clinica Belgica ·M. Hidajat, H. Deckx, M.Van Eygen, N. Logghe, A. Crie	1989	6
15	Efficacy and safety of s201086/GLPG1972, an ADAMTS-5 inhibitor, in patients with knee osteoarthritis: roccella, a 52-week, randomized, double-blind, dose-ranging phase 2 study Osteoarthritis and Cartilage ·Thomas J. Schnitzer, María Pueyo, H. Deckx, Ellen van der Aar, Katy Bernard, Sandra S. Hatch, M. van der Stoep, S. Grankov, D. Phung, O. Imbert, Damien Chimits, K. Muller, Mark S. Hochberg, Henning Bliddal, F. Eckstein, Philip G. Conaghan	2021	5
16	FRI0539 A safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) study with increasing oral doses of glpg1972 administered daily for 29 days shows a strong biomarker effect in patients with KNEE and/or HIP OA Annals of the Rheumatic Diseases ·H. Deckx, Sarah Hatch, Martine Robberechts, Sonia Dupont, Julie Desrivot, H. Coleman, S. Larsson, André Struglics, Ellen M. van der Aar, A. Fiew	2018	3
17	Absence of a pharmacokinetic interaction of rilpivirine with the P‐glycoprotein substrate digoxin in healthy volunteers Journal of the International AIDS Society ·Herta Crauwels, H. Deckx, I Enweonye, Marita Stevens, Richard M. W. Hoetelmans	2012	2
18	Neonatal and juvenile hypothyroidism in Central Africa Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) ·Claude Hector Thilly, Pierre Bourdoux, Jean Vanderpas, Béatrice Swennen, H. Deckx, G.K. Luvuvila, François Delange, Geraldo Medeiros‐Neto, Rmb Maciel, Alfredo Halpern	1986	1
19	FRI0393 BASELINE CHARACTERISTICS OF THE STUDY POPULATION IN ROCCELLA, A PHASE 2 CLINICAL TRIAL EVALUATING THE EFFICACY AND THE SAFETY OF S201086/GLPG1972 IN PATIENTS WITH KNEE OSTEOARTHRITIS Annals of the Rheumatic Diseases ·Katy Bernard, S. Grankov, M. van der Stoep, Alain Lalande, O. Imbert, D. Phung, Damien Chimits, K. Muller, Ellen van der Aar, H. Deckx, María Pueyo, F. Eckstein	2020	1

About H. Deckx

H. Deckx is a scholar working on Virology, Rheumatology, Emergency Medicine, Infectious Diseases and Pediatrics, Perinatology and Child Health, having authored 19 papers that have together received 323 indexed citations. Recurring topics across this work include Osteoarthritis Treatment and Mechanisms (8 papers), HIV-related health complications and treatments (4 papers), HIV/AIDS drug development and treatment (4 papers), Pharmacological Effects and Toxicity Studies (3 papers), HIV Research and Treatment (3 papers), Inflammatory mediators and NSAID effects (3 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and Thyroid Disorders and Treatments (2 papers). The work is most often cited by research in Virology (78 citations), Emergency Medicine (105 citations), Infectious Diseases (120 citations), Rheumatology (81 citations) and Orthopedics and Sports Medicine (24 citations). H. Deckx has collaborated with scholars based in Belgium, United States and France. Frequent co-authors include Michael Sension, Simon Vanveggel, David A. Wohl, Chloe Orkin, Marita Stevens, F. Eckstein, Ellen van der Aar, J.E. Dumont, María Pueyo and A. T. Diplock. Their work appears in journals such as Osteoarthritis and Cartilage, Annals of the Rheumatic Diseases, Clinical Infectious Diseases, Journal of the International AIDS Society and Vaccine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact